桓科

Hanker Biopharma is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule drugs for autoimmune diseases and oncology. Headquartered in Suzhou, China, the company focuses on developing highly selective kinase inhibitors that offer improved safety and efficacy over existing treatments. Its lead candidate, HK-010, is a potent and selective TYK2 inhibitor currently in Phase 2 clinical trials for plaque psoriasis and is being explored for other inflammatory conditions. Hanker's research platform emphasizes medicinal chemistry excellence to target well-validated biological pathways with next-generation chemical entities. The company is backed by prominent venture capital firms and led by a management team with extensive global pharmaceutical R&D experience.